The merger with Biopharma Excellence will allow PharmaLex to strengthen its existing operations in biopharma services.
Frankfurt, Germany – 6th October 2020: PharmaLex Group, a leading provider of specialized services for pharma, biotech and medical device industries worldwide, has completed the merger of Biopharma Excellence GmbH.
Biopharma Excellence (BPE) is a consultancy based in Munich (Germany) who offers specialized biopharma consulting services, including biologicals, antibody-containing products, cell- and gene therapies / ATMPs, biosimilars, and vaccines. Founded in 2013 by Dr. Diane Seimetz and Dr. Gabriele Dallmann, BPE supports national and global life science companies from top 10 pharma organizations to emerging start-ups. They offer integrated product development services in the EU, the US and further territories, covering early and late stage scientific, regulatory and strategic support up to submission of dossiers and lifecycle strategies.
“We are very excited to join an organization with an excellent reputation like PharmaLex, especially to bundle our complementary services”, explained Dr. Diane Seimetz, Founding Partner, Biopharma Excellence. “Our experience in strategic guidance and operational support for early to late-stage development programs supports PharmaLex’s objective to further develop their biopharma service division”, she added. “We have a long-standing reputation in biopharmaceutical consulting and therefore this merger is the right continuation of our work, to become part of a large market leading service provider”, explained Dr. Gabriele Dallmann, Founding Partner, Biopharma Excellence. “We are very much looking forward to building on the existing biopharma unit of PharmaLex and supporting its development”, she added.
“The Biopharma Excellence brand is very well recognized in the market for providing strategic advice from the very earliest stages of development of a biopharma product up to approval”, explained Dr. Thomas Dobmeyer, CEO PharmaLex. “With demand for biopharma services growing, our intention is to develop the Biopharma Excellence brand into a key service line of PharmaLex which will focus on providing high value services in the area of biopharmaceuticals and integrated product development”, he added. “In line with the Biopharma Excellence motto of providing targeted solutions for the development and approval of products and supporting companies to excel, the two companies will join forces to continue their commitment to excellence”, added Dr. Kirsten Jacobs, Managing Director, PharmaLex Germany.
About PharmaLex <Confidence beyond compliance>:
PharmaLex is a leading provider of specialised services for the pharma, biotech and medical device industries. We guide you from early strategic planning activities and non-clinical requirements through clinical development, regulatory submission processes and post-approval / maintenance post-launch activities. Our experts use technology-enabled solutions to support you through the entire product lifecycle. We deliver exceptional results — going above and beyond the standard to deliver tailor-made solutions worldwide.
The PharmaLex Group now has over 1000 employees, with 34 offices in 21 countries and more than 600 satisfied clients worldwide.
For further information, please contact: